The anticipated market size for the global portal hypertension management market by 2033 is US$ 4.97 billion, with a forecasted value of US$ 3.05 billion in 2023 and a compound annual growth rate (CAGR) of 5% from 2023 to 2033. Concludes a report that Future Market Insights recently released. With the spectrum of diagnosis covering beta-blockers, somatostatin and its analogues, and vasopressin and its analogues, the generic pharmaceutical segment currently dominates the market. This also suggests great possibilities for research and development in the field of medicine.
One of the most frequent causes of portal hypertension is cirrhosis. Cirrhosis is a liver illness that occurs when scar tissue displaces healthy liver cells. As a consequence, the number of individuals suffering from this disease is expected to drive market expansion. Cirrhosis is more prevalent in males than in females, based on the National Institute of Diabetes and Digestive and Kidney Diseases Trusted Source. As a result, the aged citizenry is anticipated to contribute to market expansion.
Discover Our Expert Analysis with Our Sample Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-16585
High cost technological innovations in the health care system and ramping up prevalence and frequency of beta-blocker consumption, North America has the highest market portion. Due to its expanding elderly population and greater diagnosis percentage, Asia-Pacific has the second-largest market revenue. As a result of perpetual increases in the incidence and occurrence of rare diseases, as well as the enhancement inpatient population, North America is forecast to account for the majority of the market in the following decade
The expansion of the Liver Transplantation segment can be linked to the global rise in demand for transplantable organs. As reported by the U.S. Department of Health and Human Services, there were roughly 122,913 diagnoses in the United States ready for organ transplants in 2019. As a result, developed transplantation items for the intervention of organ damage are in high demand. As a result, the market for the Liver Transplantation segment is growing.
Key Takeaways from the Market Study:
- From 2018 to 2022, sales witnessed major growth, registering a CAGR of 3%
- The global portal hypertension management market is predicted to garner a market value of US$ 97 Billion.
- Portal hypertension management market in North America is expected to grow at a CAGR of 4%
- Endoscopic therapy to be most preferred, expected to grow at a CAGR of 7%.
- The Asia Pacific market is expected to account for 40% of the market share.
“The therapies under advancement are focused on novel approaches to treating/improving disease signs. Companies involved are working on developing Portal Hypertension therapies. The launch of new treatments will have a significant impact on the portal hypertension management market.” says FMI’s analyst.
Connect With Our Analyst To Address Any Inquiries You May Have! https://www.futuremarketinsights.com/ask-question/rep-gb-16585
Competitive Landscape:
Key players in the Portal Hypertension Management market are Ono Pharmaceutical Co., Ltd., Chiasma, Inc., Genextra S.p.a., Gilead Sciences, Inc., Debiovision, Inc., Govind Ballabh Pant Hospital, Dr. Falk Pharma GmbH, Novartis AG, Sun Pharmaceuticals Industries Ltd. Some recent developments by manufacturers are below
- In August 2022, ONO received approval in Japan for Onoact® for Intravenous Infusion 50mg/150mg (“Onoact”), a short-acting selective 1 blocker.
- In March 2021, Gilead Sciences announced that it would expand its collaboration with Novo Nordisk and gain knowledge of the prospects for composite strategies in helping patients with cirrhosis caused by NASH, contributing to the portal hypertension management market.
Key Segments Profiled in the Portal Hypertension Management Industry Survey:
By Treatment:
- Liver Transplantation
- Endoscopic Therapy
- Banding
- Balloon Tamponade
- Shunting Procedures
- Nonsurgical Transjugular Intrahepatic Portal Systemic Shunt
- Surgical Shun
- Drug Class
- Octapeptides
- Cofactors
- PDE5 Inhibitor
- Beta Blockers
By End Users:
- Hospitals
- Specialty Clinic
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Unlocking the Power of Personalization: Embrace Customization in Our Latest Report! https://www.futuremarketinsights.com/customization-available/rep-gb-16585
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
